Follow this innovation
[ via 
] [?]
Markers of Prognosis and Therapy in Carcinomas
University of Pittsburgh
posted on 10/30/2007
Cancer cells can evade therapies as a result of defects in the DNA damage response. This invention provides a biomarker for determining which cancers have a specific genetic feature that suggests that they will respond to a specific adjunctive biologic pathway inhibitor to facilitate sensitivity and reduce resistance to radiation therapy and/or chemotherapy.
Suggested Uses
- Determination of a selective population of cancer patients more likely to respond to radiation and/or chemotherapy with the addition of a CHEK1 inhibitor to their treatment regimen.
- Use in Head and Neck carcinoma and possibly other tumors such as carcinomas, melanoma and multiple myeloma.
Advantages
- Biomarker can identify tumors that will responsive to CHEK1 inhibitors
- Biomarker can be easily detected by several molecular genetic assays
- Biomarker also may serve as a prognostic marker for head and neck cancers as well as other carcinomas
Detailed Description
This biomarker indicates those cancer patients who should be given CHEK1 inhibitors in conjunction with their radiation and/or chemotherapy to improve treatment outcome.
File Number: 1395
This innovation currently is not available for online licensing. Please contact Maria Vanegas at University of Pittsburgh for more information.
request more info
ProfileFind more innovations
